Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 11.55B P/E 20.04 EPS this Y 15.20% Ern Qtrly Grth 10.60%
Income 52.21B Forward P/E 19.05 EPS next Y 4.70% 50D Avg Chg 14.00%
Sales 271.3B PEG 7,404.76 EPS past 5Y 21.80% 200D Avg Chg 23.00%
Dividend 58.00% Price/Book 0.28 EPS next 5Y 0.21% 52W High Chg -
Recommedations 2.00 Quick Ratio 1.65 Shares Outstanding 166.53M 52W Low Chg 39.00%
Insider Own - ROA 12.38% Shares Float 119.82M Beta 0.34
Inst Own 15.15% ROE 21.39% Shares Shorted/Prior 751K/709.29K Price 69.35
Gross Margin 58.28% Profit Margin 19.24% Avg. Volume 230,151 Target Price 80.16
Oper. Margin 24.74% Earnings Date - Volume 277,826 Change 0.10%
About Dr. Reddy's Laboratories Ltd

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Dr. Reddy's Laboratories Ltd News
03/22/24 Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
03/19/24 Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
02/28/24 Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
02/05/24 Why Doctor Reddy's (RDY) is a Top Momentum Stock for the Long-Term
02/02/24 Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
02/01/24 Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q3 2024 Earnings Call Transcript
02/01/24 Dr. Reddy's (RDY) Q3 Earnings and Revenues Surpass Estimates
01/31/24 Dr. Reddy’s Q3 & 9M FY24 Financial Results
01/03/24 Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands
12/14/23 Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index
12/06/23 Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
10/30/23 Dr. Reddy's (RDY) Q2 Earnings and Revenues Beat Estimates
10/29/23 Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q2 2024 Earnings Call Transcript
10/27/23 Dr. Reddy’s Q2 FY24 Financial Results
10/26/23 All You Need to Know About Doctor Reddy's (RDY) Rating Upgrade to Strong Buy
10/04/23 3 Reasons Growth Investors Will Love Doctor Reddy's (RDY)
09/26/23 Doctor Reddy's (RDY) Loses -6.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
09/18/23 Here is Why Growth Investors Should Buy Doctor Reddy's (RDY) Now
08/31/23 Looking for a Growth Stock? 3 Reasons Why Doctor Reddy's (RDY) is a Solid Choice
08/10/23 Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.
RDY Chatroom

User Image StockInvest_us Posted - 4 hours ago

Signal alert: $RDY - Possible Runner https://stockinvest.us/l/sYAFOmTU2J

User Image StockInvest_us Posted - 1 week ago

Signal alert: $RDY - GoldenStar https://stockinvest.us/l/jo1cWKeNoC

User Image Doozio Posted - 2 weeks ago

3wt bahhhtom of base. Get da huckleberries n da 🧠 is $rdy in 🧠⏰

User Image briefingcom Posted - 2 weeks ago

$RDY: Dr. Reddy's and Bayer (BAYRY) entered into a partnership to market and distribute a second brand of Vericiguat in India https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240405085300RDY&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

User Image StockInvest_us Posted - 3 weeks ago

Signal alert: $RDY - GoldenStar https://stockinvest.us/l/5b5xGFmzL7

User Image DonCorleone77 Posted - 03/27/24

$RDY $SNY Dr. Reddy's enters partnership with Sanofi to distribute vaccines in India Dr. Reddy's Laboratories (RDY) announced that it has entered into an exclusive partnership with Sanofi Healthcare India (SNY) to promote and distribute Sanofi's vaccine brands across private markets in India. Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's pediatric and adult vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim. Sanofi will continue to own, manufacture, and import these brands to the country.

User Image briefingcom Posted - 1 month ago

$RDY: Dr. Reddy's and Pharmazz have entered into a licensing agreement to market Centhaquine as a resuscitative agent for hypovolemic shock in India https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240322070555RDY&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

User Image MakingDreamsReality Posted - 1 month ago

PM mOOvers 👀 $FDX - FedEx Q3 EPS $3.86 Beats $3.45 Estimate, Sales $21.70B Miss $22.04B Estimate,FedEx Corp. Board Of Directors Has Also Authorized A New $5B Share Repurchase Program, In Addition To The Existing $0.6B That Remains Available For Repurchase Under The 2021 Authorization $UPS -UPS shares are trading higher in sympathy with FedEx, which gained after reporting Q3 earnings. $RDY -Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India $BLIN - Automotive Accessories Manufacturer Selects Bridgeline For AI-Powered Search Platform, HawkSearch $SMLP - Summit Midstream Partners, LP shares are trading higher after the company announced the sale of its Utica position for $625 million.

User Image StockInvest_us Posted - 1 month ago

Signal alert: $RDY - GoldenStar https://stockinvest.us/l/yQs0GN7tj2

User Image Stock_Titan Posted - 1 month ago

$RDY Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK https://www.stocktitan.net/news/RDY/dr-reddy-s-laboratories-launches-versavo-r-bevacizumab-in-the-fup7uz50fntq.html

User Image StockInvest_us Posted - 1 month ago

Signal alert: $RDY - GoldenStar https://stockinvest.us/l/JAy9pLJARo

User Image Lectin_Pectin Posted - 1 month ago

$COYA $AMLX news today is a net positive for Coya. Their ALS drug was FDA approved but failed their post approval pivotal trial. This shows FDA desperation and motivation to help make something work for ALS patients. One could argue that this adds additional risk as drugs can fail after approval... However Coya has shown large magnitude of response and robust biomarker analysis which largely alleviates, but doesn't eliminate, that concern. Because of this Amylyx failure, $RDY would be foolish not to place a fat bid for Coya. They'll want to own all the IP and have (sort of) no competition in ALS (unless you consider $BIIB which is specifically for SOD1 mutation and also doesn't work much even in those 15% of patients). Reddy's can use ALS approval to finance development of FTD, and also larger, more expensive trials in other neurodegen such as AD, PD. They can buy up to $2 billion in revenue (near term!) and a whole pipeline in a drug for $1 billion...

User Image StockInvest_us Posted - 1 month ago

Signal alert: $RDY - GoldenStar https://stockinvest.us/l/DYlN4K3eKE

User Image Lectin_Pectin Posted - 02/29/24

$COYA $RDY Great video today on Schwab. IR doing a great job IMO.

User Image microcapspeculator Posted - 02/29/24

$COYA Soon on @SchwabNetwork around 10:20am ET: Coya’s CEO, Dr. Howard Berman, and @drreddys CEO of North America Generics, Marc Kikuchi, will discuss why the treatment of neurodegenerative diseases is at the forefront of our research & more. Stream: schwabnetwork.com $COYA $RDY https://twitter.com/CoyaTx/status/1763202465040650266?t=itd0XdZSErwBR3p6o-Tf6g&s=19

User Image StockInvest_us Posted - 02/29/24

Signal alert: $RDY - GoldenStar https://stockinvest.us/l/1ZwTUCuftt

User Image StockInvest_us Posted - 02/28/24

Signal alert: $RDY - GoldenStar https://stockinvest.us/l/NI68bTUmwc

User Image StockInvest_us Posted - 2 months ago

Signal alert: $RDY - GoldenStar https://stockinvest.us/l/L0Kp9vF1Ts

User Image StockInvest_us Posted - 2 months ago

Signal alert: $RDY - Overbought Trend Short (Overvalued) https://stockinvest.us/l/CktmrhDO1b

User Image Doozio Posted - 2 months ago

$COYA 🧠⏰ is $rdy ….

User Image StockInvest_us Posted - 2 months ago

Signal alert: $RDY - GoldenStar https://stockinvest.us/l/wjWIu4WR3B

User Image Doozio Posted - 2 months ago

@tctranfo @Stocktwits 🍿. Thanks FOUR shoutout. Wasn’t this stream who met 👑 Howard. Just some 🐑 acting as if. A 🦄👑 will be fine. It’s just in 🐑 slayer mode digesting its 2020 move. Forget 🚗s. That’s like practice. This is AI the actually game. Whoever was texting 👑 Howard prolly just telling him that $$$$ never sleeps. Especially when the 🧠 is $rdy and going thru da $$$ patterns as it’s growing on 🌲’s while SKWD n diverged 🐑 are selling down Jon SNOW! Chop chop huckleberries.. 2020FOUR 🧠⏰

User Image Doozio Posted - 2 months ago

🧠 is on outside. This is whUt it 👀 like wen da 🧠 is $rdy with huckleberries n $ patterns in 🧠⏰. 🐑 need to be a TAYD moar bullish!

User Image Doozio Posted - 2 months ago

🐑 are worried about breadth n being diverged while da 🧠 is $rdy n on da TRAK with huckleberries n $ patterns in 🧠⏰

User Image epsguid Posted - 01/31/24

$RDY reported earnings of $0.99, consensus was $0.87 via @eWhispers #epsbeat http://eps.sh/d/rdy

User Image Thestocktraderhubzee Posted - 01/29/24

$RDY Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $80

User Image Nosh Posted - 3 months ago

$RDY $EWZ sold these...bought $GILD $PDD on these dips. Small gains on the first two but they are not moving like I thought they would be. GLTY.

User Image cctranscripts Posted - 3 months ago

Dr. Reddy&#39,s Laboratories: Dr. Reddy’S Laboratories Ltd https://www.conferencecalltranscripts.org/summary/?id=12879329 $RDY

User Image risenhoover Posted - 3 months ago

$RDY / Dr. Reddy's Laboratories Limited - Depositary Receipt () files form 6-K https://fintel.io/doc/sec-dr-reddys-laboratories-ltd-1135951-6k-2024-january-19-19741-9155?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

Analyst Ratings
Barclays Overweight Jan 29, 24
Barclays Overweight Jun 1, 23
Barclays Overweight Oct 31, 22
Barclays Overweight Oct 25, 22
Barclays Overweight Sep 12, 22
Barclays Overweight Jul 25, 22
Barclays Overweight May 24, 22
Barclays Overweight Nov 1, 21
Barclays Overweight Feb 2, 21